BioVie Presents Data Highlighting Baseline Characteristics of Study Population in Phase 3 Trial of NE3107 in Mild to Moderate Alzheimer’s Disease

In this article:
BioVie, Inc.BioVie, Inc.
BioVie, Inc.
Advertisement